Chair and Department of Paediatrics and Paediatric Nursing, Pomeranian Medical University, 70-204 Szczecin, Poland.
Szczecin Outpatient Clinic, 71-050 Szczecin, Poland.
Nutrients. 2024 Sep 2;16(17):2949. doi: 10.3390/nu16172949.
The aim of our study was to investigate whether a 1-month-long milk-free diet results in a reduction in faecal calprotectin (FC) and faecal-zonulin-related proteins (FZRP) in children with milk-protein-induced allergic proctocolitis (MPIAP).
This is a single-centre, prospective, observational cohort study involving 86 infants with MPIAP, aged 1-3 months, and 30 healthy controls of the same age. The FC and FZRP were marked using the ELISA method (IDK Calprotectin or Zonulin ELISA Kit, Immunodiagnostik AG, Bensheim, Germany). The diagnosis of MPIAP was confirmed with an open milk challenge test.
FFC and FZRP proved useful in evaluating MPIAP treatment with a milk-free diet, and the resolution of allergic symptoms and a significant ( = 0.0000) decrease in the concentrations of both biomarkers were observed after 4 weeks on the diet. The FC and FZRP concentrations were still higher than in the control group. A high variability of FC concentrations was found in all the study groups. An important limitation is the phenomenon of FZRP not being produced in all individuals, affecting one in five infants.
FC and FZRP can be used to monitor the resolution of colitis in infants with MPIAP treated with a milk-free diet, indicating a slower resolution of allergic inflammation than of allergic symptoms. The diagnosis of MPIAP on the basis of FC concentrations is subject to considerable error, due to the high individual variability of this indicator. FZRP is a better parameter, but this needs further research, as these are the first determinations in infants with MPIAP.
我们的研究旨在探讨为期 1 个月的无牛奶饮食是否会导致牛奶蛋白诱导的过敏性直肠结肠炎(MPIAP)患儿粪便钙卫蛋白(FC)和粪便-肠紧密连接蛋白相关蛋白(FZRP)减少。
这是一项单中心、前瞻性、观察性队列研究,纳入 86 名 1-3 月龄患有 MPIAP 的婴儿和 30 名相同年龄的健康对照者。采用 ELISA 法(IDK 钙卫蛋白或肠紧密连接蛋白 ELISA 试剂盒,德国宾海姆免疫诊断股份公司)标记 FC 和 FZRP。MPIAP 的诊断采用开放牛奶挑战试验确认。
FC 和 FZRP 可用于评估无牛奶饮食治疗 MPIAP 的效果,在饮食 4 周后,过敏症状缓解,两种生物标志物的浓度均显著( = 0.0000)下降。FC 和 FZRP 浓度仍高于对照组。所有研究组的 FC 浓度均存在高度变异性。一个重要的局限性是 FZRP 并非所有个体都产生,影响五分之一的婴儿。
FC 和 FZRP 可用于监测无牛奶饮食治疗 MPIAP 患儿结肠炎的缓解情况,表明过敏炎症的缓解速度比过敏症状慢。基于 FC 浓度诊断 MPIAP 会出现较大误差,因为该指标个体差异较大。FZRP 是一个更好的参数,但需要进一步研究,因为这是首次在 MPIAP 婴儿中进行测定。